Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 24, 2026
Pacira Biosciences, Inc. (PCRX)
A forensic read on Pacira Biosciences, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Safe
Financial health
3.6
Distress distance
Clean
Earnings quality
4
Forensic signals
67.2
P / E (ttm)
1.0%
ROE
$982M
Market cap
3.6%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Pacira Biosciences, Inc. earns a C (Mixed — selective) forensic quality grade, and its balance-sheet distress test reads 3.6, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
339d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 246 to 339 FY2024→FY2025 (against cost of goods sold; inventory +22% vs -12% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
1.3%
FY2025
Return on invested capital.Return on invested capital is 1.3% in the latest fiscal year, against 7% in FY2021, having run between -5.0% and 6.9% across FY2021–FY2025 with no direction held — well below the ~10% cost of capital we hold this sector to, and it has been across FY2011–FY2025, so reinvested dollars have not been earning their keep. The capital base behind it cannot be compared across FY2021–FY2025: short-term debt and long-term debt are tagged in one of those two fiscal years and not the other, and an untagged line enters this calculation as zero, so any change in the base would be a change in what the filer tagged.
109% of FCF
FY2025
Shareholder returns.Returned $148M to shareholders (buybacks + dividends) in FY2025 — 109% of free cash flow. Right at the limit of what free cash flow covers — little room before it's funded by debt or the balance sheet. That ratio has been CLIMBING toward the limit — 0% of free cash flow a few years back — not just sitting there. Counting the $58M of stock-based comp paid out in shares on top of that, the combined claim on free cash flow is 151%.
$163M
FY2024–FY2024
Goodwill impairments.Took $163M of goodwill writedowns across 1 year (FY2024 ($163M)). Writedowns mean past acquisitions underperformed what was paid for them.
Key fundamentals
Latest Revenue$726.4M
Revenue Growth YoY+3.6%
Revenue CAGR (3yr)+2.9%
Net Margin1.0%
Free Cash Flow$136.7M
Return on Equity1.0%
Debt / Equity0.54x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Pacira Biosciences, Inc.'s actual 10-K/10-Q/8-K filings?